Amycretin vs CagriSema: Novo Nordisk’s Two Amylin Bets Compared

Novo Nordisk is pursuing two different ways to combine amylin with GLP-1 for weight loss, and amycretin and CagriSema represent that split strategy: one packs both actions into a single molecule, the other combines two separate drugs. Both are investigational. CagriSema is further along and has larger confirmed weight-loss data, while amycretin offers the convenience potential of a pill and a high ceiling. Here’s how Novo’s two amylin approaches compare.

Same Idea, Different Design

Both drugs harness the same insight: amylin and GLP-1 are separate appetite-regulating hormones, and hitting both produces more weight loss than either alone. But they execute it differently. CagriSema is a combination of two drugs (cagrilintide, an amylin analog, plus semaglutide, a GLP-1 drug) delivered together as a weekly injection. Amycretin is a single molecule engineered to activate both the amylin and GLP-1 receptors on its own, and it’s being developed in both injectable and oral pill forms. So it’s a combination approach versus an all-in-one molecule.

Head to Head

Weight Loss: Both Strong, CagriSema Confirmed

On weight loss, both reach impressive levels. CagriSema produced about 22.7% in its completed phase 3 REDEFINE 1 trial. Amycretin’s injectable form reached the low 20% range in earlier testing, published in The Lancet in 2025, though from smaller, earlier-stage studies. So CagriSema has the more robust, confirmed weight-loss data, while amycretin’s numbers are promising but from earlier trials. Amycretin’s oral form produces less (around 13% in short studies), which is expected for a pill.

The Key Difference: Amycretin Could Be a Pill

Amycretin’s standout advantage is format flexibility. Because it’s a single molecule, it can be formulated as an oral pill, something CagriSema (a two-drug injectable combination) can’t easily do. For patients who prefer pills or dislike injections, an oral amylin-GLP-1 drug would be appealing. Consider a hypothetical patient weighing the two: if they want the strongest confirmed injectable, CagriSema leads; if they’d prefer a pill and are willing to wait, amycretin’s oral form is the draw. CagriSema is also closer to market, having already been filed for FDA approval.

Status and Availability

Neither is available. CagriSema is further along (Novo Nordisk filed for FDA approval in late 2025), while amycretin is entering phase 3 for both its formats. Both are Novo Nordisk drugs, so the company is essentially hedging across two amylin strategies, which is a sign of how promising the amylin approach is overall.

What This Means for You Right Now

Neither amycretin nor CagriSema is available, and TrimRx does not offer them. TrimRx provides currently available options, including compounded semaglutide and compounded tirzepatide plus brand GLP-1 injectables. If you want strong weight loss now, those available options are the practical choice while Novo’s amylin drugs work through development.

Frequently Asked Questions

What’s the difference between amycretin and CagriSema?

Both combine amylin and GLP-1 action, but amycretin is a single molecule doing both (available as an injection or pill), while CagriSema is two separate drugs combined into one injection. CagriSema has more confirmed late-stage data; amycretin offers pill potential.

Which produces more weight loss?

CagriSema has the stronger confirmed result (about 22.7% in completed phase 3). Amycretin’s injectable reached the low 20% range in earlier trials, and its pill form produces less (around 13%). CagriSema’s data is more robust for now.

Are either available?

No. Both are investigational Novo Nordisk drugs available only through clinical trials. CagriSema has been filed for FDA approval; amycretin is entering phase 3. TrimRx offers approved alternatives.

To focus on treatments available today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Amycretin and CagriSema are investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.